BA
ZYNE

Bellwether Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Bellwether Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-84
Closed – – 546
2022
Q2 		$0 Hold
84
– – ﹤0.01% 605
2022
Q1 		$0 Buy
+84
New +$200 ﹤0.01% 635

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bellwether Advisors's ZYNE Position: Q3 2022 in Review

Bellwether Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2022, closing a stake of 84 shares.

Bellwether Advisors first reported a position in ZYNE in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 62 funds tracked by Wall St. Rank hold ZYNE as of Q3 2022.

  • Bellwether Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2022 after selling out during the quarter.
  • Bellwether Advisors sold 84 Zynerba Pharmaceuticals, Inc shares in Q3 2022.
  • Bellwether Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2022 and held it in 2 quarters.
  • Bellwether Advisors's Zynerba Pharmaceuticals, Inc position peaked at $0 in Q2 2022.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2022.

Based on Bellwether Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.